NCT02775617 - Azithromycin - Ivermectin Mass Drug Administration for Skin Disease | Biotech Hunter

Enrollment

1,291

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

February 5, 2018

Conditions

ScabiesYawsImpetigo

Interventions

DRUG

Ivermectin

Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Ivermectin will be offered as a a single dose 200μg/kg on Day 1 and Day 8.

DRUG

Azithromycin

Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Azithromycin will be offered as single dose of 30mg/kg, max 2G.

DRUG

Permethrin

Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Individuals with a contra-indication to ivermectin will be offered Permethrin instead.

Trial Locations (1)

Unknown

Atoifi Adventist Hospital, Atoifi